Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

IDDO and MORU released its Medicine Quality Scientific Literature Surveyor. The surveyor delivers summaries of published scientific reports on the quality of the classes of essential medicines listed below, across regions and over time. We hope it will help medicine regulators, scientists, health professionals, purchasers and officials fill critical information gaps.

Africa and Asia map

Substandard and falsified (SF) medical products (medicines, vaccines, diagnostic tests and devices) pose an immediate danger to many people worldwide, and in the case of anti-infectives, they could also increase the threat of drug resistance emerging and spreading. A major challenge in preventing this is a lack of accessible and reliable information on how widespread they really are. This new mapping tool visualises these data and it will help scientists, health professionals and officials fill critical information gaps. 

Funded by Wellcome, the tool delivers summaries of published scientific reports on the quality of communicable diseases (antimalarials, antiretrovirals, antibiotics, anti-tuberculosis) non-communicable diseases (antidiabetics and medical devices for diabetes management, cardiovascular medicines and medical devices), veterinary medicines, and vaccines across regions and over time, both in English and French.

It builds on the success of the Medicine Quality team’s work on WWARN’s existing Antimalarial Surveyor and future phased releases are planned that will expand its reach to other medical products.  

With increasing number of reports in the scientific literature of substandard and falsified medical products for diagnosis, treatment and prevention of COVID-19 we are developing a Surveyor database and map for these, including past reports of SF medicines being repurposed for COVID-19.

Read more on the IDDO website

Similar stories

Check-list recommended to improve reporting of microscopy methods and results in malaria studies

@Oxford Publication Research

A study to explore the variations of how microscopy methods are reported in published malaria studies has recommended standardised procedures should be implemented for methodological consistency and comparability of clinical trial outcomes.

UK National Health Service begins rollout of Oxford coronavirus vaccine

@Oxford General

The first patients are being vaccinated as part of the UK’s rollout of the Oxford / AstraZeneca coronavirus vaccine, ChAdOx1 nCoV-19, at the Oxford University NHS Hospitals Trust. The Oxford AstraZeneca vaccinations will be delivered at a small number of hospitals for the first few days for surveillance purposes, as is standard practice, before the bulk of supplies are sent to hundreds of GP-led services later in the week.

Susie Dunachie awarded flagship NIHR career development award

@Oxford Awards & Appointments

Susie Dunachie joins a prestigious group of leading health researchers in the latest cohort of NIHR Global Research Professors. These awards fund research leaders of the future to promote effective translation of research and to strengthen health, public health and care research leadership at the highest academic levels. Research conducted by Global Research Professors directly benefits people in LMICs. A Consultant in Infectious Diseases and Medical Microbiology, Susie works on the development of a vaccine to prevent death from melioidosis in people with type 2 diabetes mellitus in LMICs, and supports vaccine research in Thailand. Congratulations!

RECOVERY trial finds no benefit from azithromycin in patients hospitalised with COVID-19

@Oxford Research

Established in March 2020, the RECOVERY trial tests a range of potential treatments for COVID-19, including azithromycin, a widely used antibiotic that also reduces inflammation. The azithromycin arm of the trial was established to determine whether or not the drug has a meaningful benefit among patients hospitalised with COVID-19. A preliminary analysis shows no significant difference in the primary endpoint of 28-day mortality; there was also no evidence of beneficial effects on the risk of progression to mechanical ventilation or length of hospital stay.

AfOx receives the Wellcome Institutional Strategic Support Fund to launch the Africa Health Innovation Platform

@Oxford

AfOx in collaboration with partners across the UK and Africa has received a Wellcome Institutional Strategic Support Fund to establish an Africa Health Innovation Platform. The multi-disciplinary platform will support African innovators who develop new solutions to Africa’s health challenges, bringing together researchers, entrepreneurs, investors, technologists, policymakers, and change leaders to develop new approaches towards prevention, early detection and treatment of diseases.

The COVID-19 vaccine: do we know enough to end the pandemic?

@Oxford MORU

Blog by Rima Shretta. Preliminary efficacy results from three vaccine candidates currently in Phase 3 trials have shown an efficacy of more than 90% against the development of symptomatic COVID-19. While these results are promising, all vaccines are in relatively early stages of testing. A comprehensive and transparent roadmap is urgently needed, to determine how limited doses of the first vaccines to be licensed will be distributed, together with which groups will initially be prioritized.